middl
east
respiratori
syndrom
coronaviru
merscov
identifi
caus
agent
sever
lethal
respiratori
diseas
occur
across
sever
countri
middl
east
date
laboratori
confirm
case
merscov
countri
case
fatal
rate
given
endem
region
possibl
merscov
could
spread
annual
hajj
pilgrimag
necessit
countermeasur
develop
report
describ
clinic
radiograph
chang
rhesu
monkey
follow
infect
pfu
merscov
two
group
nhp
treat
either
human
antim
monoclon
antibodi
antihiv
antibodi
merscov
infect
result
quantifi
chang
comput
tomographi
limit
clinic
sign
diseas
treat
subject
develop
significantli
reduc
lung
patholog
compar
infect
untreat
subject
indic
antibodi
may
suitabl
merscov
treatment
publish
elsevi
inc
septemb
novel
coronaviru
discov
patient
suffer
sever
acut
respiratori
diseas
term
middl
east
respiratori
syndrom
mer
subsequ
viru
renam
merscov
de
groot
et
al
thu
far
nation
report
mer
case
case
fatal
rate
http
wwwwhointemerg
merscoven
fortun
merscov
yet
demonstr
sustain
human
human
transmiss
howev
given
estim
million
pilgrim
merscov
endem
region
hajj
merscov
repres
continu
global
health
risk
despit
substanti
respons
health
agenc
merscov
infect
continu
spread
geograph
due
travel
evidenc
recent
outbreak
republ
korea
case
death
singl
case
thailand
philippin
china
http
unfortun
definit
reservoir
yet
identifi
although
camel
heavili
implic
may
least
serv
intermedi
host
camel
may
provid
intervent
point
prevent
human
diseas
adney
et
al
gossner
et
al
khalafalla
et
al
yusof
et
al
merscov
abl
establish
effici
human
human
transmiss
maintain
pathogen
increas
number
patient
special
care
requir
could
rapidli
place
strain
healthcar
resourc
treatment
thu
far
support
report
patient
place
extracorpor
membran
oxygen
commonli
known
ecmo
maintain
health
pebodi
et
al
date
merscovspecif
countermeasur
treatment
program
develop
mer
countermeasur
develop
depend
appropri
anim
model
ideal
laboratori
anim
model
would
uniformli
recapitul
sever
outcom
human
diseas
date
three
murin
model
report
express
merscov
receptor
human
dipeptidyl
peptidas
respiratori
track
adenoviru
transduct
airway
zhao
et
al
construct
transgen
human
mice
genom
techniqu
agraw
et
al
pascal
et
al
mous
model
serv
complementari
role
evalu
medic
countermeasur
channappanavar
et
al
channappanavar
et
al
merscov
respiratori
diseas
agraw
et
al
lung
patholog
pascal
et
al
common
marmoset
callithrix
jacchu
also
evalu
mer
model
falzarano
et
al
johnson
et
al
develop
limit
diseas
shown
histopatholog
analysi
radiolog
analysi
qrtpcr
evid
viru
replic
lung
develop
sever
respiratori
diseas
faith
replic
human
condit
nonhuman
primat
model
import
part
drug
discoveri
process
close
phylogenet
related
human
use
grant
regulatori
approv
move
human
clinic
trial
nonhuman
primat
nhp
macaca
mulatta
model
mer
describ
two
group
yao
et
al
model
exposur
rhesu
monkey
merscov
lead
transient
lung
infect
result
variabl
lung
patholog
consist
inflammatori
infiltr
well
transient
radiolog
lung
find
howev
date
report
use
model
evalu
new
antim
drug
renew
interest
use
monoclon
antibodi
treat
viral
infect
review
bossart
et
al
marasco
sui
qiu
kobing
shadman
wald
other
identifi
neutral
antibodi
merscov
jiang
et
al
tang
et
al
ying
et
al
studi
describ
intratrach
inocul
rhesu
monkey
merscov
well
pilot
studi
demonstr
efficaci
human
monoclon
antibodi
merscov
spike
protein
reduc
lung
patholog
follow
merscov
infect
experi
perform
two
part
initi
part
establish
rhesu
merscov
infect
model
use
merscov
mersjor
second
part
evalu
antimerscov
monoclon
antibodi
total
five
group
nhp
evalu
shown
fig
comput
tomographi
ct
chosen
standard
radiographi
ct
quantifi
allow
direct
comparison
group
reduc
bia
ct
provid
represent
region
interest
wherea
standard
radiographi
compress
imag
dimens
may
misrepres
patholog
studi
two
subject
group
inocul
pfu
mersjor
receiv
period
bronchoalveolar
lavag
bal
determin
impact
infect
procedur
viral
antigen
would
lung
patholog
measur
ct
group
consist
two
subject
receiv
pfu
mersjor
intratrach
inocul
without
bal
determin
impact
viru
lung
patholog
two
subject
group
receiv
pfu
infecti
mersjor
period
bal
determin
impact
bal
observ
lung
patholog
group
subject
rechalleng
day
determin
immun
enhanc
diseas
match
patholog
find
radiolog
find
bal
also
perform
group
subject
follow
rechalleng
group
consist
three
subject
receiv
pfu
infecti
viru
inocul
preced
treatment
day
prior
infect
final
group
compris
subject
receiv
pfu
infecti
viru
inocul
preced
treatment
antibodi
zwick
et
al
day
prior
infect
nonspecif
control
antibodi
physic
examin
daili
observ
indic
merscov
infect
rhesu
develop
obviou
clinic
sign
mer
bodi
temperatur
measur
rectal
within
normal
rang
rhesu
monkey
fig
peripher
oxygen
satur
measur
respiratori
function
decreas
normal
valu
fig
sign
respiratori
diseas
tussi
dyspnea
observ
although
mild
increas
fig
group
rhesu
monkey
challeng
infect
pfu
mersjor
viru
shown
period
ct
blood
draw
perform
n
repres
number
subject
group
underw
indic
procedur
variat
number
procedur
perform
given
day
logist
determin
base
blood
withdraw
limit
access
ct
subject
given
complet
physic
exam
prior
ct
blood
withdraw
respiratori
rate
sporad
observ
group
subject
fig
data
indic
mersjor
infect
advers
impact
lung
function
complet
blood
count
differenti
cbcdiff
reinforc
physic
examin
data
clinic
signific
chang
observ
fig
slight
lymphopenia
could
observ
group
day
postinfect
slight
neutropenia
day
postinfect
group
mild
leukopenia
day
postinfect
cbcdiff
group
follow
rechalleng
compar
initi
day
postinfect
period
data
suggest
overt
immun
enhanc
diseas
occur
mersjor
infect
rhesu
monkey
qrtpcr
whole
blood
nasal
swab
bal
sampl
perform
determin
viral
load
dissemin
site
infect
qrtpcr
result
limit
detect
day
across
group
sampl
indic
detect
dissemin
merscov
lung
peripher
organ
limit
viru
replic
obtain
data
acut
phase
diseas
progress
subject
group
challeng
third
time
studi
day
one
subject
group
necropsi
day
postinfect
plaqu
assay
lung
liver
kidney
homogen
neg
serial
passag
tissu
homogen
cell
suggest
mersjor
replic
restrict
tissu
evalu
chang
lung
architectur
result
mersjor
infect
visual
quantit
analys
perform
briefli
lung
volum
interest
automat
extract
quantifi
use
patholog
lung
delin
algorithm
high
sensit
specif
mansoor
et
al
procedur
follow
statist
machinelearn
scheme
call
random
forest
classif
patholog
tissu
identif
tissu
morpholog
quantif
includ
volum
densiti
properti
total
temperatur
respiratori
rate
peripher
oxygen
satur
within
normal
rang
rhesu
monkey
b
cbcdiff
data
indic
limit
respons
merscov
inocul
wbc
lymphocyt
neutrophil
monocyt
total
count
within
normal
rang
although
chang
observ
hash
line
indic
normal
valu
rang
group
mock
blue
squar
group
pfu
orang
triangl
group
green
circl
pfu
wbal
arrow
indic
challeng
rechalleng
day
shade
background
repres
differ
phase
experi
initi
challeng
follow
challeng
interpret
refer
color
figur
legend
reader
refer
web
version
articl
lung
capac
refin
ad
patholog
tissu
lung
region
interest
roi
patholog
percentag
comput
use
total
lung
capac
diseas
sever
index
averag
valu
compar
group
fig
adjust
differ
total
lung
volum
subject
percent
patholog
lung
volum
also
calcul
fig
data
also
support
mild
respiratori
diseas
ct
abnorm
shown
peak
valu
effect
member
group
demonstr
differ
observ
lung
patholog
across
group
fig
two
subject
group
one
two
subject
group
group
imag
per
day
schedul
shown
fig
peak
observ
lung
patholog
subject
within
group
averag
peak
respons
initi
day
follow
challeng
ct
quantif
indic
peak
lung
patholog
observ
group
averag
day
postinfect
st
dev
group
peak
lung
patholog
observ
averag
day
st
dev
averag
day
st
dev
group
mean
peak
percentag
abnorm
lung
volum
group
st
dev
group
st
dev
group
st
dev
data
suggest
inocul
procedur
result
lung
patholog
mersjor
infect
result
limit
viru
specif
diseas
bal
may
exacerb
lung
patholog
group
rechalleng
day
postinocul
similar
pattern
increas
abnorm
lung
volum
occur
day
postinfect
follow
rechalleng
day
similar
initi
challeng
subject
develop
increas
lung
diseas
compar
initi
infect
suggest
immuneenhanc
diseas
occur
experi
follow
second
infect
serial
ct
indic
averag
peak
percentag
abnorm
lung
volum
st
dev
occur
averag
day
st
dev
postsecond
infect
group
subject
st
dev
also
occur
day
st
dev
postsecond
infect
group
subject
follow
rd
infect
day
initi
infect
peak
lung
patholog
occur
averag
day
st
dev
postinfect
averag
abnorm
lung
volum
percentag
st
dev
group
averag
day
postinfect
averag
abnorm
lung
volum
st
dev
group
fig
first
part
experi
demonstr
mersjor
exposur
result
quantifi
lung
patholog
therefor
sought
determin
efficaci
human
antimerscov
monoclon
antibodi
group
treat
antihiv
antibodi
respect
day
prior
infect
subject
given
period
physic
exam
blood
draw
ct
monitor
diseas
progress
potenti
efficaci
supplement
fig
repres
ct
shown
fig
quantif
serial
ct
indic
treatment
result
reduc
lung
patholog
compar
control
antibodi
fig
patholog
lung
volum
group
treat
peak
averag
day
postinfect
st
dev
averag
abnorm
lung
volum
percentag
st
dev
one
subject
demonstr
abnorm
lung
volum
group
subject
demonstr
peak
increas
abnorm
lung
volum
percentag
day
postinfect
subject
averag
st
dev
abnorm
lung
volum
data
support
conclus
left
panel
total
abnorm
lung
volum
quantifi
ct
data
group
data
demonstr
lung
patholog
transient
rechalleng
result
increas
lung
patholog
right
panel
quantif
ct
percentag
total
lung
volum
asterisk
indic
day
peak
lung
patholog
observ
individu
subject
group
mock
blue
squar
group
pfu
orang
triangl
group
pfu
wbal
green
circl
arrow
indic
challeng
rechalleng
day
shade
background
repres
differ
phase
experi
initi
challeng
follow
challeng
b
repres
ct
select
subject
group
demonstr
peak
lung
patholog
interpret
refer
color
figur
legend
reader
refer
web
version
articl
pretreat
merscov
specif
monoclon
antibodi
inhibit
mersjor
induc
lung
patholog
model
comparison
antibodi
treat
group
unpair
twotail
ttest
use
graphpad
prism
indic
signific
differ
comparison
treat
subject
untreat
merscov
infect
subject
unpair
twotail
ttest
use
graphpad
prism
indic
signific
differ
observ
lung
patholog
evalu
base
patholog
lung
volum
fig
diseas
lung
volum
calcul
percentag
total
lung
volum
fig
similar
pattern
observ
statist
signific
differ
observ
antibodi
treatment
found
howev
signific
differ
observ
treat
group
group
infect
untreat
subject
group
unpair
twotail
ttest
use
graphpad
prism
statist
differ
group
also
support
linear
mix
model
analysi
fig
experi
perform
separ
stage
statist
analysi
use
linear
mix
model
use
evalu
abnorm
lung
volum
measur
laird
ware
shown
fig
statist
significantli
differ
observ
group
group
group
group
statist
signific
group
group
indic
bal
may
exacerb
lung
patholog
impact
bal
must
account
respiratori
diseas
model
lowest
observ
pvalu
comparison
group
suggest
merscov
antibodi
inhibit
develop
abnorm
lung
patholog
statist
signific
differ
establish
group
group
group
group
signific
differ
group
group
observ
group
gray
diamond
treatment
result
statist
significantli
po
decreas
lung
patholog
compar
untreat
infect
group
untreat
infect
subject
group
orang
triangl
includ
comparison
c
statist
comparison
group
support
bal
exacerb
diseas
day
group
analyz
linear
mix
model
summar
mean
differ
standard
error
p
valu
given
tabl
p
valu
use
provid
stringent
basi
signific
comparison
statist
signific
differ
bold
interpret
refer
color
figur
legend
reader
refer
web
version
articl
group
subject
euthan
group
subject
euthan
day
postinfect
signific
patholog
chang
observ
group
group
ct
data
indic
medial
lung
patholog
may
follow
track
inoculum
deposit
therefor
lung
lobe
histolog
evalu
individu
histopatholog
result
summar
tabl
histolog
examin
lung
reveal
multifoc
interstiti
lymphohistocyt
infiltr
pulmonari
congest
pulmonari
edema
epitheli
cell
degener
grossli
major
differ
observ
day
day
necropsi
subject
subject
demonstr
diffus
pulmonari
congest
vari
degre
demonstr
tracheobronchi
lymph
node
enlarg
one
subject
group
hepat
discolor
subject
retrospect
diagnos
amyloidosi
signal
merscov
antigen
detect
immunohistochemistri
select
lung
sampl
examin
bal
sampl
evalu
histolog
contain
predominantli
alveolar
macrophag
approx
diamet
mani
pseudopodia
lymphocyt
red
blood
cell
ciliat
respiratori
epitheli
cell
background
proteinaceousmucin
materi
small
amount
surfact
cellular
debri
clinic
signific
pathogen
seen
lung
examin
em
goal
experi
establish
rhesu
model
mer
laboratori
determin
efficaci
human
monoclon
antibodi
merscov
experi
nhp
develop
limit
clinic
sign
diseas
develop
quantifi
virusinduc
chang
lung
architectur
follow
exposur
rhesu
monkey
mersjor
also
demonstr
monoclon
antibodi
merscov
significantli
reduc
virusinduc
lung
patholog
measur
ct
compar
untreat
subject
thu
warrant
investig
potenti
merscov
countermeasur
present
studi
vari
previou
studi
merscov
rhesu
monkey
due
use
mersjor
ct
evalu
structur
chang
lung
comparison
subject
receiv
bal
subject
euthan
earli
timepoint
postinfect
evalu
patholog
viral
load
subject
rechalleng
determin
immun
enhanc
infect
may
occur
mersjor
infect
rhesu
previous
describ
differ
observ
studi
munster
yao
yao
et
al
indic
merscov
isol
evalu
determin
improv
model
could
develop
overal
mersjor
inocul
rhesu
monkey
result
mild
diseas
result
conjunct
yao
et
al
merscov
emc
rhesu
monkey
experi
demonstr
mild
diseas
strike
clinic
featur
lack
overt
clinic
sign
limit
util
mersrhesu
monkey
model
howev
medic
imag
standard
radiographi
ct
may
provid
altern
biomark
diseas
munster
et
al
yao
et
al
also
report
structur
chang
lung
use
standard
radiographi
howev
standard
radiographi
limit
provid
view
region
interest
subject
interpret
bias
improv
standard
radiographi
use
ct
provid
quantifi
measur
patholog
standard
studi
depend
upon
avail
equip
studi
merscov
induc
diseas
progress
regress
measur
ct
subject
develop
lung
patholog
could
observ
day
postinfect
peak
day
postinfect
follow
similar
pattern
subsequ
rechalleng
group
subject
differ
group
group
anim
observ
like
due
continu
bal
procedur
perform
group
subject
furthermor
comparison
group
subject
group
suggest
procedur
bal
like
induc
increas
lung
patholog
may
confound
studi
result
describ
previous
haley
et
al
von
essen
et
al
de
wit
et
al
perform
bal
day
postinfect
yao
et
al
perform
bal
less
respiratori
diseas
observ
radiographi
yao
et
al
support
find
bal
influenc
radiolog
find
howev
crosslaboratori
comparison
difficult
due
differ
methodolog
avail
equip
inher
variabl
interpret
radiogram
chosen
base
initi
character
antibodi
escap
mutant
isol
highest
viru
neutral
abil
abil
produc
larg
quantiti
demonstr
pretreat
monoclon
antibodi
merscov
spike
protein
significantli
reduc
sever
lung
patholog
compar
untreat
subject
lung
patholog
treat
subject
roughli
control
antibodi
treat
subject
roughli
equal
subject
receiv
viru
bal
group
lack
statist
signific
control
antibodi
like
due
small
variabl
volum
lung
patholog
induc
merscov
small
group
size
n
pvalu
comparison
treatment
nearli
reach
signific
p
support
larger
group
size
may
provid
statist
signific
differ
pilot
studi
pave
way
experi
util
larger
group
size
vari
treatment
strategi
includ
post
exposur
treatment
trigger
treat
base
ct
find
experi
would
also
need
includ
control
group
media
viru
account
possibl
viru
may
also
induc
inflammatori
respons
must
note
two
subject
advanc
age
assign
group
year
old
year
old
age
subject
group
demonstr
roughli
three
time
elev
abnorm
lung
patholog
ml
total
lung
volum
compar
two
subject
group
ml
averag
total
lung
volum
cours
studi
subject
diagnos
diabet
although
specul
find
support
human
clinic
observ
comorbid
diabet
may
increas
diseas
sever
human
develop
potenti
antimerscov
treatment
nhp
model
would
also
involv
potenti
use
subject
comorbid
similar
find
munster
laboratori
yao
et
al
includ
transient
respiratori
diseas
primarili
medial
lack
sustain
fever
develop
mild
chang
white
blood
cell
count
limit
chang
peripher
oxygen
satur
inflammatori
infiltr
lung
de
wit
et
al
yao
et
al
find
contrast
previous
publish
result
viral
rna
infecti
viru
could
detect
bal
lung
nasal
oral
swab
qrtpcr
attempt
isol
infecti
viru
qrtpcr
data
indic
viru
replic
limit
follow
mersjor
infect
may
due
differ
rhesu
human
receptor
merscov
raj
et
al
merscov
infect
steadili
continu
sinc
identif
region
affect
continu
middl
east
recent
outbreak
republ
korea
reinforc
need
continu
monitor
merscov
develop
countermeasur
greater
understand
viral
pathogenesi
anim
model
faith
mimic
human
diseas
need
develop
identif
evalu
potenti
countermeasur
well
understand
diseas
process
rhesu
monkey
marmoset
develop
sever
diseas
observ
human
yao
et
al
falzarano
et
al
johnson
et
al
date
avail
nonhuman
primat
model
small
anim
model
particularli
mice
explor
well
model
provid
greater
access
nhp
model
avail
knockout
mice
transgen
mice
transduct
model
provid
opportun
studi
specif
diseas
process
thu
far
two
commonli
studi
isol
mersemc
mersjor
isol
evalu
avail
model
identifi
isol
may
provid
higher
degre
pathogenesi
rel
restrict
host
evalu
date
improv
model
emerg
viral
pathogen
develop
merscov
propag
cell
multipl
infect
moi
day
cell
maintain
eagl
modifi
essenti
medium
emem
hyclon
logan
ut
supplement
fetal
bovin
serum
fb
sigma
st
loui
mo
co
cell
maintain
emem
supplement
fb
penicillin
streptomycin
co
viru
recov
remov
tissu
cultur
media
follow
low
speed
centrifug
g
min
remov
cellular
debri
store
titer
limit
dilut
plaqu
assay
vero
cell
atcc
evalu
mycoplasma
endotoxin
contamin
gene
encod
express
igg
use
viralbas
transient
express
system
magnicon
giritch
et
al
use
host
plant
transient
express
infect
recombin
agrobacterium
tumefacien
strasser
et
al
mab
purifi
previous
describ
zeitlin
et
al
greater
puriti
assess
sdspage
hplcsizeexclus
chromatographi
twelv
rhesu
monkey
macaca
mulatta
rang
weight
kg
year
old
screen
prior
enrol
simian
retroviru
srv
simian
tlymphotroph
viru
stlv
subject
divid
five
group
group
receiv
proven
inactiv
viru
group
receiv
pfu
mersjor
group
receiv
pfu
mersjor
bronchoalveolar
lavag
inocula
perform
ml
emem
placement
endotrach
tube
cm
carina
follow
ml
pb
air
flush
ensur
deliveri
inoculum
group
receiv
mgkg
antibodi
iv
infus
anim
procedur
perform
nation
institut
allergi
infecti
diseas
divis
clinic
research
integr
research
facil
approv
nation
institut
allergi
infecti
diseas
divis
clinic
research
anim
care
use
committe
adher
nation
institut
health
nih
polici
prior
post
inocul
comput
tomographi
ct
physic
exam
includ
temperatur
weight
perform
blood
draw
swab
oral
nasal
caviti
taken
day
day
postinocul
group
subject
pediatr
bronchoscop
guid
bronchoalveolar
lavag
perform
subject
maintain
isofluran
ct
procedur
nhp
monitor
least
twice
daili
euthan
met
establish
endpoint
criteria
preestablish
scale
use
evalu
subject
health
diseas
progress
criteria
includ
overal
clinic
appear
labor
breath
activ
behavior
respons
core
bodi
temperatur
subject
met
moribund
clinic
endpoint
criteria
day
post
initi
inocul
day
post
third
inocul
nhp
human
euthan
blood
oral
nasal
swab
collect
select
tissu
excis
virolog
histopatholog
analysi
describ
group
subject
euthan
acquir
high
resolut
breathhold
chest
ct
data
hybrid
philip
preced
spectct
scanner
specif
design
function
environ
use
kvp
mm
axial
field
view
mm
slice
thick
mm
increment
cover
whole
lung
reconstruct
perform
matrix
use
lung
filter
individu
subject
lung
region
interest
roi
initi
segment
normal
lung
parenchyma
volum
determin
use
fuzzi
connected
base
imag
segment
algorithm
mansoor
et
al
subsequ
randomforest
base
machinelearn
algorithm
appli
determin
volum
spatial
extent
patholog
region
ad
lung
roi
mainli
ground
glass
opac
consolid
observ
patholog
tissu
therefor
machinelearn
algorithm
tune
optim
detect
abnorm
imag
pattern
apart
normal
tissu
normal
patholog
tissu
identifi
percent
abnorm
lung
comput
total
patholog
tissu
volum
divid
total
lung
capac
airway
airway
wall
also
delin
use
graphbas
segment
algorithm
xu
et
al
explor
whether
infect
reach
affect
airway
howev
find
signific
volum
densiti
chang
either
airway
airway
wall
similar
routin
use
evalu
candid
vaccin
approach
merscov
wang
et
al
complet
blood
cell
differenti
count
cbcdiff
determin
blood
sampl
collect
ethylenediaminetetraacet
acid
edta
coat
blood
tube
analyz
use
sysmex
sysmex
america
mundelein
il
serum
chemistri
valu
assay
use
piccolo
cmp
panel
plaqu
assay
perform
tissu
sampl
excis
necropsi
necropsi
tissu
flash
frozen
store
wv
homogen
gener
serial
fold
dilut
made
incub
confluent
cell
overlay
tragacanth
follow
incub
tragacanth
overlay
remov
monolay
stain
crystal
violet
crystal
violet
ethanol
formalin
vv
plaqu
enumer
group
subject
necropsi
day
post
inocul
forti
one
tissu
major
organ
system
collect
fix
neutral
buffer
formalin
follow
fixat
nbf
tissu
trim
thick
section
place
cassett
tissu
dehydr
seri
grade
alcohol
clear
organ
solvent
infiltr
molten
paraggin
sakura
tissu
tek
vip
tissu
processor
sakura
vip
process
tissu
place
mold
embed
paraffin
mccormick
paraplast
plu
result
block
section
mm
use
rotari
microtom
float
water
bath
pick
superfrost
plu
gold
slide
fisher
section
bake
min
hematoxylin
eosin
h
e
stain
appli
use
leica
autom
stain
system
leica
stain
slide
examin
via
standard
light
microscopi
detect
merscov
antigen
immunohistochemistri
perform
use
rabbit
polyclon
antiserum
merscov
sino
biolog
primari
antibodi
detect
antigen
tissu
uninfect
control
anim
use
valid
immunohistochemistri
procedur
h
e
section
examin
light
microscopi
veterinari
pathologist
lh
ultrastructur
morpholog
investig
collect
bal
fix
glutaraldehyd
em
scienc
warrington
pa
usa
millonig
sodium
phopshat
buffer
tousimi
research
rockvil
md
usa
h
preserv
cell
postfix
osmium
tetroxid
em
scienc
en
bloc
stain
uranyl
acet
dehydr
grade
ethanol
seri
embed
spurr
plastic
resin
em
scienc
embed
block
section
use
leica
ultramicrotom
leica
nm
ultrathin
section
collect
mount
mesh
copper
grid
contrast
lead
cirat
grid
examin
imag
use
fe
tecnai
transmiss
electron
microscop
oper
kb
tecnai
viral
load
sampl
determin
quantit
pcr
use
upe
assay
describ
corman
et
al
sampl
extract
trizol
screen
presenc
merscov
use
specif
primer
abi
limit
detect
gene
copi
compar
group
differ
lung
patholog
data
day
day
analyz
linear
mix
model
use
take
correl
within
subject
account
laird
ware
reflect
possibl
nonlinear
effect
day
use
linear
quadrat
cubic
term
day
effect
data
analys
perform
splu
due
multipl
comparison
problem
stringent
p
valu
less
claim
signific
